Last reviewed · How we verify
Tuckahoe
Tuckahoe is a Small molecule drug developed by Macrohard Institute of Health. It is currently in Phase 1 development. Also known as: One of active ingredients in TCM group.
Tuckahoe is a term that may refer to a Native American word, and it has been studied in clinical trials for various conditions including Polycystic Ovary Syndrome, Chronic Renal Failure, Hemodialysis, Irritable Bowel Syndrome, and Gastrointestinal Disease. The Bushen Huatan Decoction, which is associated with Tuckahoe, has been used as an intervention in clinical trials for these conditions.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tuckahoe |
|---|---|
| Also known as | One of active ingredients in TCM group |
| Sponsor | Macrohard Institute of Health |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Bushen Huatan Decoction in the Treatment of Polycystic Ovary Syndrome (PHASE1, PHASE2)
- Effects of Shenkang Decoction on Creatinine and Blood Urea Nitrogen in Chronic Renal Failure Hemodialysis Patients (EARLY_PHASE1)
- Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Non-organic Gastrointestinal Disorders (NA)
- Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST) (NA)
- A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome (NA)
- The Evaluation Studies of Curative Effect of Fu-zheng-qu-zhuo Oral Liquid in Treatment of Ischemic Nephropathy (PHASE2, PHASE3)
- Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tuckahoe CI brief — competitive landscape report
- Tuckahoe updates RSS · CI watch RSS
- Macrohard Institute of Health portfolio CI
Frequently asked questions about Tuckahoe
What is Tuckahoe?
Who makes Tuckahoe?
Is Tuckahoe also known as anything else?
What development phase is Tuckahoe in?
Related
- Manufacturer: Macrohard Institute of Health — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: One of active ingredients in TCM group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing